Latest Research, Industry, Medical and Scientific News
Urology in the Lab starts off with data from a study that very strongly implicates Epstein-Barr virus (EBV) as the causative agent underlying multiple sclerosis (MS), a demyelinating disease that often finds its way into the urology clinic due to neurogenic bladder that can develop during the course of disease. Read more.
Urology Times, November 27, 2023
The first sign of trouble was difficulty reading. In late 2014 Cathy A. Haft, a New York real estate broker who divides her time between Brooklyn and Long Island, thought she needed new glasses. But an eye exam found that her prescription was largely unchanged. Bladder problems came next, followed by impaired balance, intermittent dizziness and unexplained falls. By 2018 Haft, unable to show properties because she was too unsteady on her feet, was forced to retire. Read more.
Source: Washington Post, November 25, 2023
Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence (SUI). Following this clearance, Versameb plans to launch a Phase 2a open label, first-in-human dose ascending study in the first half of 2024. The study will evaluate the safety, tolerability, and efficacy of VMB-100 in female subjects with stress urinary incontinence, a highly common condition resulting in involuntary leakage of urine due to a weakened urinary sphincter muscle. Read more.
Source: Pharmaweb.com, November 17, 2023
Avation Medical, Inc., an innovative neuromodulation and digital health company with a mission to make wearable peripheral neuromodulation accessible to patients across a variety of clinical conditions, today announced the publication of safety and efficacy results from a multi-center study, “FREEOAB”, for its novel Vivally System in Urology, a leading, peer–reviewed journal for urologists. “The Vivally System represents a significant advancement in bladder control therapy as a non-invasive, patient-centered therapy providing patients with effective treatment, performed in the home, without the need for surgery or drugs,” said Dr. Colin Goudelocke, Principal Investigator for the FREEOAB Study. “In our study, significant reductions in symptom burden were observed at 12 weeks which, notably, persisted out to 12 months, even with a reduction in frequency of therapy sessions.” Read more.
Source: PRNewswire, November 15, 2023
New international research on the economic burden of urinary incontinence reveals that the cost of continence care will reach an estimated €69.1 billion in 2023. These costs include the impact of incontinence on individuals’ health, the costs of medical consultations and products such as continence pads, incontinence-related absenteeism at work, nursing home admissions, and the environmental impact of incontinence care. If no action is taken to support continence health, the economic burden could rise by 25% in 2030, to €86.7 billion. This economic burden becomes considerably higher when including caregiver costs. Read more.
Source: EurekAlert!, November 7, 2023
This recorded webinar intends to clarify the value of (data-driven) Shared Decision-making (SDM) in the management of incontinence. Learning Objectives: -The benefits and value of data-driven SDM. -How can urologists facilitate (data-driven) shared decision-making with their patients? -The need for patient reported outcomes in the management of incontinence. Speakers: Dr. M.R. Van Balken (NL) Mrs. M.L. Van Poelgeest-Pomfret (NL) Mr. J. Phillips (GB) Mrs. J. Ghith (US) This recorded webinar is brought to you in collaboration with WFIPP. Link to the recorded webinar: https://www.youtube.com/watch?v=b7bhMjVsPUY
Source: November 2, 2023